Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity
Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity
Summary
GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.
Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.
GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 8.9% during the period 2010-2017 from $1,154.9m in 2010 to $2,095.9m by 2017. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.
GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2010-2017. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.
GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.
Scope
Summary
GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.
Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.
GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 8.9% during the period 2010-2017 from $1,154.9m in 2010 to $2,095.9m by 2017. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.
GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2010-2017. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.
GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.
Scope
- Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
- Market forecasts for the seasonal influenza vaccines from 2010 to 2017
- Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
- Key drivers and restraints that have created significant impact on the market.
- Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
- Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
- Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the seasonal influenza vaccine market.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.
Contents
1 TABLE OF CONTENTS1.1 List of Tables
1.2 List of Figures
2 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - INTRODUCTION
2.1 GBI Research Report Guidance
3 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - MARKET OVERVIEW
3.1 Production Cycle for the Seasonal Influenza Vaccines
3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market
3.3 Revenue for the Seasonal Influenza Vaccine Market
3.4 Geographical Segmentation
4 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - GEOGRAPHICAL LANDSCAPE
4.1 Australia
4.1.1 Vaccination Pattern
4.1.2 Cost of Vaccine
4.1.3 Total Revenue
4.2 New Zealand
4.2.1 Vaccination Pattern
4.2.2 Cost of Vaccine
4.2.3 Total Revenue
4.2.4 Major Players by Market Share
4.3 Taiwan
4.3.1 Vaccination Pattern
4.3.2 Cost of Vaccine
4.3.3 Total Revenue
4.3.4 Major Players by Market Share
4.4 Philippines
4.4.1 Vaccination Pattern
4.4.2 Cost of Vaccine
4.4.3 Total Revenue
4.4.4 Major Players by Market Share
4.5 Malaysia
4.5.1 Vaccination Pattern
4.5.2 Cost of Vaccine
4.5.3 Total Revenue
4.5.4 Major Players by Market Share
4.6 Hong Kong
4.6.1 Vaccination Pattern
4.6.2 Cost of Vaccine
4.6.3 Total Revenue
4.6.4 Major Players by Market Share
4.7 Singapore
4.7.1 Vaccination Pattern
4.7.2 Cost of Vaccine
4.7.3 Total Revenue
4.7.4 Major Players by Market Share
4.8 Japan
4.8.1 Vaccination Pattern
4.8.2 Cost of Vaccine
4.8.3 Total Revenue
4.8.4 Major Players in the Market
4.9 China
4.9.1 Vaccination Pattern
4.9.2 Cost of Vaccine
4.9.3 Total Revenue
4.9.4 Major Players in the Market
4.10 India
4.10.1 Vaccination Pattern
4.10.2 Cost of Vaccine
4.10.3 Total Revenue
4.10.4 Major Players in the Market
5 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - DRIVERS AND RESTRAINTS
5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region
5.1.1 Threat of Pandemic Influenza
5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines
5.1.3 Emergence of Novel Production Technologies and Vaccines
5.1.4 Population Growth
5.1.5 Economic Reasons
5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region
5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market
5.2.2 Variable Demand
5.2.3 Limited Production Capacity
5.3 Australia
5.3.1 Drivers
5.3.2 Restraints
5.4 New Zealand
5.4.1 Drivers
5.4.2 Restraints
5.5 Taiwan
5.5.1 Drivers
5.5.2 Restraints
5.6 Philippines
5.6.1 Drivers
5.6.2 Restraints
5.7 Malaysia
5.7.1 Drivers
5.7.2 Restraints
5.8 Hong Kong
5.8.1 Drivers
5.8.2 Restraints
5.9 Singapore
5.9.1 Drivers
5.9.2 Restraints
5.10 Japan
5.10.1 Drivers
5.10.2 Restraints
5.11 China
5.11.1 Drivers
5.11.2 Restraints
5.12 India
5.12.1 Drivers
5.12.2 Restraints
6 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - REGULATORY LANDSCAPE
6.1 Registration Process and Regulations in Australia
6.2 Registration Process and Regulations in New Zealand
6.3 Registration Process and Regulations in Taiwan
6.4 Registration Process and Regulations in the Philippines
6.5 Registration Process and Regulations in Malaysia
6.6 Registration Process and Regulations in Hong Kong
6.7 Registration Process and Regulations in Singapore
6.8 Registration Process and Regulations in Japan
6.9 Registration Process and Regulations in China
6.10 Registration Process and Regulations in India
7 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - PIPELINE ANALYSIS
7.1 Seasonal Influenza Vaccines - Promising Vaccines under Clinical Development
7.2 Profiles for Promising Vaccines under Clinical Development
7.2.1 Optaflu
7.2.2 GSK2186877A
7.2.3 Intanza / Flu-ID
7.2.4 Fluad Pediatric
7.2.5 FluBlok
7.3 Research and Development Pipeline
8 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - COMPETITIVE LANDSCAPE
8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region
8.1.1 Fluarix
8.1.2 Vaxigrip
8.1.3 Influvac
8.1.4 Fluvax
8.1.5 Agrippal
8.2 Key Areas Focused for R&D
8.3 Competitive Profiling
8.3.1 Sanofi Pasteur
8.3.2 GlaxoSmithKline Biologicals
8.3.3 Abbott Laboratories (Solvay Pharmaceuticals)
8.3.4 CSL Biotherapies
8.3.5 Novartis Vaccines
8.3.6 Crucell N.V. (Berna Biotech)
9 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - M&A LANDSCAPE
9.1 Overview
9.2 Major Merger and Acquisition Deals, 2007-2011
9.2.1 AstraZeneca Acquires Medimmune
9.2.2 Sanofi-Aventis (now Sanofi) Acquires Acambis
9.2.3 Mymetics Acquires Virosome Biologicals
9.2.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock
9.2.5 Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan
9.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals
9.2.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno
9.2.8 Johnson & Johnson Acquires Crucell
9.2.9 GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals
9.3 M&A Deals by Year of Completion, 2007-2011
9.4 M&A Deals by Geography
9.5 Major Licensing Agreements, 2007-2011
9.5.1 Crucell enters into License Agreement with Adimmune Corporation
9.5.2 MedImmune Enters into Licensing Agreement with Sanofi Pasteur
9.5.3 Vivalis enters into Licensing Agreement with GlaxoSmithKline
9.5.4 Vivalis enters into Licensing Agreement with Nobilon International
9.5.5 MedImmune enters into Licensing Agreement with GlaxoSmithKline
9.5.6 Hemispherx Biopharma Enters Into Licensing Agreement with BIKEN
9.5.7 MedImmune Enters Into Licensing Agreement with BIKEN
9.5.8 MedImmune Enters Into Licensing Agreement with Omninvest
9.5.9 OPKO Health Enters Into Licensing Agreement with Academia Sinica
9.5.10 AltraVax Enters Into Licensing Agreement with Maxygen
9.5.11 Protein Sciences Expands Its Licensing Agreement with UMN Pharma for FluBlok and PanBlok
9.5.12 NasVax Extends Its Research Agreement with Novartis
9.5.13 iBio Enters Into Licensing Agreement With G-Con
9.6 Licensing Deals by Year of Completion, 2007-2011
9.7 Licensing Deals by Geography
10 SEASONAL INFLUENZA VACCINE MARKET IN ASIA-PACIFIC REGION - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 The Scope of the Study
10.3.3 Secondary Research
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources
LIST OF TABLES
Table 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue, ($m), 2010-2017
Table 2: Seasonal Influenza Vaccine Market, Australia, Population (‘000), 2010-2017
Table 3: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Table 4: Seasonal Influenza Vaccine Market, Australia, Overall Vaccination Coverage (‘000), 2010 - 2017
Table 5: Seasonal Influenza Vaccine Market, Australia, Vaccination Coverage Break-up by Age Groups (‘000), 2010-2017
Table 6: Seasonal Influenza Vaccine Market, Australia, Overall Number of Doses (‘000), 2010-2017
Table 7: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Age Groups, (‘000), 2010-2017
Table 8: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Purchase Sector, (‘000), 2010-2017
Table 9: Seasonal Influenza Vaccine Market, Australia, Cost of Vaccine,($), 2010-2017
Table 10: Seasonal Influenza Vaccine Market, Australia, Revenue, ($m), 2010-2017
Table 11: Seasonal Influenza Vaccine Market, Australia, Revenue Breakdown, ($m), 2010-2017
Table 12: Seasonal Influenza Vaccine Market, New Zealand, Population (‘000), 2010-2017
Table 13: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution (%), 2010-2017
Table 14: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Table 15: Seasonal Influenza Vaccine Market, New Zealand, Overall Vaccination Coverage (‘000), 2010-2017
Table 16: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Coverage by Age Groups (‘000), 2010-2017
Table 17: Seasonal Influenza Vaccine Market, New Zealand, Overall Number of Doses (‘000), 2010-2017
Table 18: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Age Groups (‘000), 2010-2017
Table 19: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Sector Contribution (‘000), 2010-2017
Table 20: Seasonal Influenza Vaccine Market, New Zealand Cost of Vaccine, ($), 2010-2017
Table 21: Seasonal Influenza Vaccine Market, New Zealand, Revenue, ($m), 2010-2017
Table 22: Seasonal Influenza Vaccine Market, New Zealand, Revenue Breakdown, ($m), 2010-2017
Table 23: Seasonal Influenza Vaccine Market, Taiwan, Population (‘000), 2010-2017
Table 24: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Table 25: Seasonal Influenza Vaccine Market, Taiwan, Overall Vaccination Coverage (‘000), 2010-2017
Table 26: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Coverage by Age Groups (‘000), 2010-2017
Table 27: Seasonal Influenza Vaccine Market, Taiwan, Overall Number of Doses (‘000), 2010-2017
Table 28: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Age Groups (‘000), 2010-2017
Table 29: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Sector Contribution (‘000), 2010-2017
Table 30: Seasonal Influenza Vaccine Market, Taiwan, Cost of Vaccine, ($), 2010-2017
Table 31: Seasonal Influenza Vaccine Market, Taiwan, Revenue, ($m), 2010-2017
Table 32: Seasonal Influenza Vaccine Market, Taiwan, Revenue Breakdown, ($m), 2010-2017
Table 33: Seasonal Influenza Vaccine Market, Philippines, Population (‘000), 2010-2017
Table 34: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Table 35: Seasonal Influenza Vaccine Market, Philippines, Overall Vaccination Coverage (‘000), 2010-2017
Table 36: Seasonal Influenza Vaccine Market, Philippines, Vaccination Coverage by Age Groups (‘000), 2010-2017
Table 37: Seasonal Influenza Vaccine Market, Philippines, Overall Number of Doses (‘000), 2010-2017
Table 38: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Age Groups (‘000), 2010-2017
Table 39: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Sector Contribution (‘000), 2010-2017
Table 40: Seasonal Influenza Vaccine Market, Philippines, Cost of Vaccine, ($), 2010-2017
Table 41: Seasonal Influenza Vaccine Market, Philippines, Revenue, ($m), 2010-2017
Table 42: Seasonal Influenza Vaccine Market, Philippines, Revenue Breakdown, ($m), 2010-2017
Table 43: Seasonal Influenza Vaccine Market, Malaysia, Population (‘000), 2010-2017
Table 44: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccinated Population Contribution (%), 2010-2017
Table 45: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Table 46: Seasonal Influenza Vaccine Market, Malaysia, Overall Vaccination Coverage (‘000), 2010-2017
Table 47: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Coverage by Age Groups (‘000), 2010-2017
Table 48: Seasonal Influenza Vaccine Market, Malaysia, Overall Number of Doses (‘000), 2010-2017
Table 49: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Age Groups (‘000), 2010-2017
Table 50: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Sector Contribution (‘000), 2010-2017
Table 51: Seasonal Influenza Vaccine Market, Malaysia, Cost of Vaccine, ($), 2010-2017
Table 52: Seasonal Influenza Vaccine Market, Malaysia, Revenue, ($m), 2010-2017
Table 53: Seasonal Influenza Vaccine Market, Malaysia, Revenue Breakdown, ($m), 2010-2017
Table 54: Seasonal Influenza Vaccine Market, Hong Kong, Population (‘000), 2010-2017
Table 55: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Table 56: Seasonal Influenza Vaccine Market, Hong Kong, Overall Vaccination Coverage (‘000), 2010-2017
Table 57: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Coverage by Age Groups (‘000), 2010-2017
Table 58: Seasonal Influenza Vaccine Market, Hong Kong, Overall Number of Doses (‘000), 2010-2017
Table 59: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Age Groups (‘000), 2010-2017
Table 60: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Sector Contribution (‘000), 2010-2017
Table 61: Seasonal Influenza Vaccine Market, Hong Kong, Cost of Vaccine, ($), 2010-2017
Table 62: Seasonal Influenza Vaccine Market, Hong Kong, Revenue, ($m), 2010-2017
Table 63: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Breakdown, ($m), 2010-2017
Table 64: Seasonal Influenza Vaccine Market, Singapore, Population (‘000), 2010-2017
Table 65: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccinated Population Contribution (%), 2010-2017
Table 66: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Table 67: Seasonal Influenza Vaccine Market, Singapore, Overall Vaccination Coverage (‘000), 2010-2017
Table 68: Seasonal Influenza Vaccine Market, Singapore, Vaccination Coverage by Age Groups (‘000), 2010-2017
Table 69: Seasonal Influenza Vaccine Market, Singapore, Overall Number of Doses (‘000), 2010-2017
Table 70: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Age Groups (‘000), 2010-2017
Table 71: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Sector Contribution (‘000), 2010-2017
Table 72: Seasonal Influenza Vaccine Market, Singapore, Cost of Vaccine, ($), 2010-2017
Table 73: Seasonal Influenza Vaccine Market, Singapore, Revenue, ($m), 2010-2017
Table 74: Seasonal Influenza Vaccine Market, Singapore, Revenue Breakdown, ($m), 2010-2017
Table 75: Seasonal Influenza Vaccine Market, Japan, Population (‘000), 2010-2017
Table 76: Seasonal Influenza Vaccine Market, Japan, Vaccinated Population Contribution by Age Group (%), 2010-2017
Table 77: Seasonal Influenza Vaccine Market, Japan, Overall Vaccination Coverage (‘000), 2010-2017
Table 78: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage Break-up by Age Group (‘000), 2010-2017
Table 79: Seasonal Influenza Vaccine Market, Japan, Overall Number of Doses (‘000), 2010-2017
Table 80: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group, (‘000), 2010-2017
Table 81: Seasonal Influenza Vaccine Market, Japan, Cost of Vaccine, ($), 2010-2017
Table 82: Seasonal Influenza Vaccine Market, Japan, Revenue, ($m), 2010-2017
Table 83: Seasonal Influenza Vaccine Market, China, Population (‘000), 2010 - 2017
Table 84: Seasonal Influenza Vaccine Market, China, Vaccinated Population Contribution by Age Group (%), 2010-2017
Table 85: Seasonal Influenza Vaccine Market, China, Overall Vaccination Coverage (‘000), 2010-2017
Table 86: Seasonal Influenza Vaccine Market, China, Vaccination Coverage by Age Group (‘000), 2010-2017
Table 87: Seasonal Influenza Vaccine Market, China, Overall Number of Doses (‘000), 2010-2017
Table 88: Seasonal Influenza Vaccine Market, China, Number of Doses by Age Groups (‘000), 2010-2017
Table 89: Seasonal Influenza Vaccine Market, China, Cost of Vaccine ($), 2010-2017
Table 90: Seasonal Influenza Vaccine Market, China, Revenue, ($m), 2010-2017
Table 91: Seasonal Influenza Vaccine Market, China, Revenue Breakdown, ($m), 2010-2017
Table 92: Seasonal Influenza Vaccine Market, India, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Table 93: Seasonal Influenza Vaccine Market, India, Overall Vaccination Coverage (‘000), 2010-2017
Table 94: Seasonal Influenza Vaccine Market, India, Vaccination Coverage by Age Group (‘000), 2010-2017
Table 95: Seasonal Influenza Vaccine Market, India, Overall Number of Doses (‘000), 2010-2017
Table 96: Seasonal Influenza Vaccine Market, India, Number of Doses by Age Group (‘000), 2010-2017
Table 97: Seasonal Influenza Vaccine Market, India, Cost of Vaccine($), 2010-2017
Table 98: Seasonal Influenza Vaccine Market, India, Revenue, ($m), 2010-2017
Table 99: Seasonal Influenza Vaccine Market, India, Revenue Breakdown, ($m), 2010-2017
Table 100: Seasonal Influenza Vaccine Market, Increasing Vaccination Coverage Against Seasonal Influenza. 2010-2017
Table 101: Seasonal Influenza Vaccine Market, Vaccination Coverage Rate, (%), 2010-2017
Table 102: Seasonal Influenza Vaccine Market, Most Promising Vaccines Under Clinical Development, 2011
Table 103: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Pipeline, Filed, 2011
Table 104: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Phase III Clinical Pipeline, 2011
Table 105: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Phase II Clinical Pipeline, 2011
Table 106: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Phase I Clinical Pipeline, 2011
Table 107: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Pre-Clinical Pipeline, 2011
Table 108: Seasonal Influenza Vaccine Market, Asia-Pacific Region, Discovery Phase Pipeline, 2011
Table 109: Seasonal Influenza Vaccine Market, Asia-Pacific, Major M&A Deals, 2007-2011
LIST OF FIGURES
Figure 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue, ($m), 2010-2017
Figure 2: Seasonal Influenza Vaccine Market, APAC Region, Market Share by Country (%), 2010 and 2017
Figure 3: Seasonal Influenza Vaccine Market, Australia, Population (‘000), 2010-2017
Figure 4: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Figure 5: Seasonal Influenza Vaccine Market, Australia, Number of Doses by Age Groups, (‘000), 2010-2017
Figure 6: Seasonal Influenza Vaccine Market, Australia, Revenue, ($m), 2010-2017
Figure 7: Seasonal Influenza Vaccine Market, Australia, Revenue Breakdown, ($m), 2010-2017
Figure 8: Seasonal Influenza Vaccine Market, New Zealand, Population (‘000), 2010-2017
Figure 9: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Figure 10: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses by Age Groups (‘000), 2010-2017
Figure 11: Seasonal Influenza Vaccine Market, New Zealand, Revenue, ($m), 2010-2017
Figure 12: Seasonal Influenza Vaccine Market, New Zealand, Revenue Breakdown, ($m), 2010-2017
Figure 13: Seasonal Influenza Vaccine Market, New Zealand, Market Share by Company (%), 2010
Figure 14: Seasonal Influenza Vaccine Market, Taiwan, Population (‘000), 2010-2017
Figure 15: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Figure 16: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses by Age Groups (‘000), 2010-2017
Figure 17: Seasonal Influenza Vaccine Market, Taiwan, Revenue, ($m), 2010-2017
Figure 18: Seasonal Influenza Vaccine Market, Taiwan, Revenue Breakdown, ($m), 2010-2017
Figure 19: Seasonal Influenza Vaccine Market, Taiwan, Market Share by Company, (%), 2010
Figure 20: Seasonal Influenza Vaccine Market, Philippines, Population (‘000), 2010-2017
Figure 21: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Figure 22: Seasonal Influenza Vaccine Market, Philippines, Number of Doses by Age Groups (‘000), 2010-2017
Figure 23: Seasonal Influenza Vaccine Market, Philippines, Revenue, ($m), 2010-2017
Figure 24: Seasonal Influenza Vaccine Market, Philippines, Revenue Breakdown, ($m), 2010-2017
Figure 25: Seasonal Influenza Vaccine Market, Philippines, Market Share by Company, (%), 2010
Figure 26: Seasonal Influenza Vaccine Market, Malaysia, Population (‘000), 2010-2017
Figure 27: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Figure 28: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses by Age Groups (‘000), 2010-2017
Figure 29: Seasonal Influenza Vaccine Market, Malaysia, Revenue, ($m), 2010-2017
Figure 30: Seasonal Influenza Vaccine Market, Malaysia, Revenue Breakdown, ($m), 2010-2017
Figure 31: Seasonal Influenza Vaccine Market, Malaysia, Market Share by Company, (%), 2010
Figure 32: Seasonal Influenza Vaccine Market, Hong Kong, Population (‘000), 2010-2017
Figure 33: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Figure 34: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses by Age Groups (‘000), 2010-2017
Figure 35: Seasonal Influenza Vaccine Market, Hong Kong, Revenue, ($m), 2010-2017
Figure 36: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Breakdown, ($m), 2010-2017
Figure 37: Seasonal Influenza Vaccine Market, Hong Kong, Market Share by Company, (%), 2010
Figure 38: Seasonal Influenza Vaccine Market, Singapore, Population (‘000), 2010-2017
Figure 39: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Figure 40: Seasonal Influenza Vaccine Market, Singapore, Number of Doses by Age Groups (‘000), 2010-2017
Figure 41: Seasonal Influenza Vaccine Market, Singapore, Revenue, ($m), 2010-2017
Figure 42: Seasonal Influenza Vaccine Market, Singapore, Revenue Breakdown, ($m), 2010-2017
Figure 43: Seasonal Influenza Vaccine Market, Singapore, Market Share by Company, (%), 2010
Figure 44: Seasonal Influenza Vaccine Market, Japan, Population (‘000), 2010-2017
Figure 45: Seasonal Influenza Vaccine Market, Japan, Vaccinated Population Contribution by Age Group (%), 2010-2017
Figure 46: Seasonal Influenza Vaccine Market, Japan, Number of Doses by Age Group, (‘000), 2010-2017
Figure 47: Seasonal Influenza Vaccine Market, Japan, Revenue, ($m), 2010-2017
Figure 48: Seasonal Influenza Vaccine Market, Japan, Major Players in the Market, 2010
Figure 49: Seasonal Influenza Vaccine Market, China, Population (‘000), 2010 - 2017
Figure 50: Seasonal Influenza Vaccine Market, China, Vaccinated Population Contribution by Age Group (%), 2010-2017
Figure 51: Seasonal Influenza Vaccine Market, China, Number of Doses by Age Group (‘000), 2010-2017
Figure 52: Seasonal Influenza Vaccine Market, China, Revenue, ($m), 2010-2017
Figure 53: Seasonal Influenza Vaccine Market, China, Revenue Breakdown, ($m), 2010-2017
Figure 54: Seasonal Influenza Vaccine Market, China, Major Players in the Market, 2010
Figure 55: Seasonal Influenza Vaccine Market, India, Population (Thousands), 2010-2017
Figure 56: Seasonal Influenza Vaccine Market, India, Vaccinated Population Contribution by Age Groups (%), 2010-2017
Figure 57: Seasonal Influenza Vaccine Market, India, Number of Doses by Age Group (‘000), 2010-2017
Figure 58: Seasonal Influenza Vaccine Market, India, Revenue, ($m), 2010-2017
Figure 59: Seasonal Influenza Vaccine Market, India, Revenue Breakdown, ($m), 2010-2017
Figure 60: Seasonal Influenza Vaccine Market, India, Major Players in the Market, 2010
Figure 61: Seasonal Influenza Vaccine Market, APAC Region, Drivers and Restraints, 2010-2017
Figure 62: Seasonal Influenza Vaccine Market, Increasing Vaccination Coverage Against Seasonal Influenza. 2010-2017
Figure 63: Seasonal Influenza Vaccine Market, Vaccination Coverage Rate, (%), 2010-2017
Figure 64: Seasonal Influenza Vaccine Market, Regulatory Authorities in Australia, 2011
Figure 65: Seasonal Influenza Vaccine Market, Drug Approval Process in Australia, 2011
Figure 66: Seasonal Influenza Vaccine Market, Regulatory Authorities in New Zealand, 2011
Figure 67: Seasonal Influenza Vaccine Market, Drug Approval Process in New Zealand, 2011
Figure 68: Seasonal Influenza Vaccine Market, Regulatory Authorities in Taiwan, 2011
Figure 69: Seasonal Influenza Vaccine Market, Drug Approval Process in Taiwan, 2011
Figure 70: Seasonal Influenza Vaccine Market, Regulatory Authorities in the Philippines, 2011
Figure 71: Seasonal Influenza Vaccine Market, Drug Approval Process in Philippines, 2011
Figure 72: Seasonal Influenza Vaccine Market, Regulatory Authorities in Malaysia, 2011
Figure 73: Seasonal Influenza Vaccine Market, Drug Approval Process in Malaysia, 2011
Figure 74: Seasonal Influenza Vaccine Market, Regulatory Authorities in Hong Kong, 2011
Figure 75: Seasonal Influenza Vaccine Market, Drug Approval Process in Hong Kong, 2011
Figure 76: Seasonal Influenza Vaccine Market, Regulatory Authorities in Singapore, 2011
Figure 77: Seasonal Influenza Vaccine Market, Drug Approval Process in Singapore, 2011
Figure 78: Seasonal Influenza Vaccine Market, Regulatory Authorities in Japan, 2011
Figure 79: Seasonal Influenza Vaccine Market, Drug Approval Process in Japan, 2011
Figure 80: Seasonal Influenza Vaccine Market, Regulatory Authorities in China, 2011
Figure 81: Seasonal Influenza Vaccine Market, Drug Approval Process in China for New Drug Registration Process, 2011
Figure 82: Seasonal Influenza Vaccine Market, Regulatory Authority in India, 2011
Figure 83: Seasonal Influenza Vaccine Market, Common Technical Document, India, 2011
Figure 84: Seasonal Influenza Vaccine Market, Drug Approval Process in India, 2011
Figure 85: Seasonal Influenza Vaccine Market, Asia-Pacific Region, R&D Pipeline by Phase (%), 2011
Figure 86: Seasonal Influenza Vaccine Market, Product Pipeline of Major Players in Asia-Pacific Region, 2011
Figure 87: Seasonal Influenza Vaccine Market, Completed M&A Deals by Year, 2007-2011
Figure 88: Seasonal Influenza Vaccine Market, M&A Deals by Geography, (%), 2007-2011
Figure 89: Seasonal Influenza Vaccine Market, Completed R&D Deals by Year, 2007-2011
Figure 90: Seasonal Influenza Vaccine Market, Licensing Agreements by Geography, (%), 2007-2011
Figure 91: GBI Research Market Forecasting Model, Estimation of Market for Taiwan, $m, 2010
COMPANIES MENTIONED
Sanofi Pasteur
GlaxoSmithKline Biologicals
Abbott Laboratories (Solvay Pharmaceuticals)
CSL Biotherapies
Novartis Vaccines
Crucell N.V. (Berna Biotech) Skip to top